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Abstract
Introduction We conducted a systematic review of evidence
on the effectiveness of imatinib at escalated doses of
600 mg/day or 800 mg/day for treatment of adults with
unresectable or metastatic gastrointestinal stromal tumours
(GIST), following progression on imatinib at the 400 mg/day
dose, compared with sunitinib and/or ‘best supportive care’.
Methods Electronic searches were undertaken to identify
relevant randomised controlled trials (RCTs), non-randomised
studies, and case series reporting outcome data on survival,
quality of life or adverse events. Titles and abstracts were
screened by two reviewers and full text reports of potentially
relevant studies assessed for inclusion. Included studies were
quality assessed by two reviewers and data were extracted. Five
studies reported data on the relevant population and were
included.
Results and Discussion Median overall survival for imati-
nib (800 mg/day) and sunitinib both were less than 2 years.
Around 25% of patients required either an imatinib dose
delay or reduction. Approximately one-third of patients
receiving dose escalated imatinib (either dose) showed
either response or stable disease. Amongst those responding
to the escalated 800 mg/day dose, median progression-free
survival was over 25 months. The statistical likelihood of
response may depend on exon mutational status. There
were few data and those that were available were
potentially biased, due to their non-randomised nature.
Further data are needed to justify international guideline
recommendations on imatinib dose escalation.
Conclusion A prospective audit of management and out-
comes for unresectable GIST patients treated with dose
escalation upon progression at 400 mg/day may be
appropriate as an RCT may be unfeasible.
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Introduction
Gastrointestinal stromal tumours (GISTs) are a rare malig-
nancy, accounting for less than 1% of all cancers of the
gastrointestinal (GI) tract [1] and in Europe the annual
incidence is 15 cases per million population [2]. They are a
distinct tumour type arising from the interstitial cells of
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Cajal (ICC), characterised in 96% of cases by the expression
of the receptor tyrosine kinase KIT (CD117) protein (demon-
strable on immunohistochemistry) [3]. The 4% of GIST cases
that are KIT negative [4, 5] are more likely to contain
platelet-derived growth factor receptor alpha (PDGFRA)
mutations [4], and this and alternative markers (e.g. DOG1)
can be used to enable diagnosis if KIT immunochemistry is
negative [2].
Within the past decade, imatinib (at doses of 400 to
800mg/day) and sunitinib have been licensed for the treatment
of GIST. Prior to this, ‘best supportive care’ (e.g. to control
symptoms and pain) was the only available treatment for those
with unresectable disease. The prognosis for this patient group
was poor, with few patients surviving 2 years [6, 7].
Management of unresectable and/or metastatic GIST
typically involves commencing patients on the standard
imatinib dose of 400 mg/day. On confirmed disease
progression at this dose, decisions regarding treatment
depend on the individual’s clinical circumstances, but
options can include dose escalation of imatinib up to an
800 mg/day dose, sunitinib (within its licensed dose range)
or best supportive care [3, 8–10].
Response to imatinib is more likely in GISTs with
certain pathogenic KIT mutations. This could provide
predictive biomarkers to enable the personalisation and
optimisation of first- and second-line therapy [11]. In a
recent meta-analysis of RCTs comparing first-line use of
standard 400 mg/day imatinib with an initial 800 mg/day
dose, those with exon nine mutations had longer
progression-free survival (p=0.017), but not overall survival
(p=0.150) in the 800 mg/day arm. This suggests the
possibility that patients with exon 9 mutations may benefit
from immediate high dose imatinib treatment, as opposed to
escalation only upon disease progression [12].
However, even if individually tailored imatinib starting
doses, based on the identification of KIT mutations (or other
biomarkers), become standard clinical practice in future,
evidence on the effectiveness of escalated imatinib doses in
unresectable or metastatic disease following progression on
the 400 mg/day dose is still relevant. This is because all
patients eventually progress after an initial response and for
those on 400 mg/day, dose escalation remains an available
option [13–17]. Some of the clinically relevant molecular
mechanisms for secondary resistance to imatinib 400 mg/day
have also recently been identified, and secondary mutations
in KIT exons 13, 14, 17, and 18 are associated with acquired
resistance to imatinib [15], which may also impact on the
effectiveness of imatinib dose escalation.
The objective of this review was to determine the
relative benefit (in patients who have acquired resistance
to the 400 mg/day imatinib dose) of dose escalation (to
either 600 mg/day or 800 mg/day imatinib), sunitinib or
best supportive care.
Materials and Methods
Electronic searches of relevant databases were undertaken
to identify reports of published and ongoing studies. The
searches were designed to be sensitive, using both
controlled vocabulary and text terms. Full details of the
search strategies used can be obtained from the authors.
The databases searched were: Medline (1966—September
Wk 3 2009), Medline In-Process (25th September 2009),
Embase (1980—Week 39 2009), CINAHL (September
2009), Science Citation Index (2000—26th September
2009), Biosis (2000—24th September 2009), Health Manage-
ment Information Consortium (September 2009), and the
Cochrane Controlled Trials Register for primary research and
the Database of Abstracts of Reviews of Effects (DARE)
(October 2009), the Cochrane Database of Systematic Reviews
(CDSR; Issue 3 2009) and the HTA database for relevant
evidence syntheses (October 2009).
Ongoing and recently completed trials were identified
from current research registers, including Clinical Trials,
Current Controlled Trials, NIHR Portfolio, WHO Interna-
tional Clinical Trials Registry Platform, IFPMA Clinical
Trials and the ABPI database. Recent conference proceedings
of key oncology and gastrointestinal organisations, including
the American Society for Clinical Oncology (ASCO),
European Society for Medical Oncology (ESMO) and the
European Cancer Organisation were also searched. Websites
of the GIST Support International, and the drug manufac-
turers, Pfizer (sunitinib) and Novartis (imatinib), were also
scrutinised as were the reference lists of retrieved papers, in
order to identify additional potentially relevant studies.
Randomised controlled trials (RCTs), non-randomised
comparative studies and case series were all considered
relevant and non-English language studies were permitted.
Studies of animal models, preclinical and biological studies,
reviews, editorials, opinions, case reports and reports inves-
tigating technical aspects of the interventions were excluded.
The population of interest was adults with KIT-positive
unresectable and/or metastatic gastrointestinal stromal
tumours (GIST), whose disease had progressed on treat-
ment with imatinib on 400 mg/day. Subgroup analysis was
to be undertaken (if data were available) on patients with
differing KIT mutations.
The interventions under consideration were imatinib at
escalated doses of 600 mg/day or 800 mg/day, being
prescribed in addition to best supportive care, which was
defined to include active symptom control, pain management
and “the multi-professional attention to the individual’s
overall physical, psychosocial, spiritual and cultural needs”
[18]. The comparators considered were sunitinib (prescribed
within its recommended dose range of 25–75 mg/day and
provided in addition to best supportive care), and best
supportive care alone.
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Included studies were required to report at least one of
the following outcomes: overall response, overall survival,
disease-free survival, progression-free survival, time to
treatment failure, health-related quality of life or the
adverse effects of treatment.
Two reviewers independently screened titles and abstracts
of all records identified by the searches and assessed full-text
copies of all potentially relevant reports against the pre-
defined inclusion criteria. Screening and data extraction forms
were developed to assist in obtaining relevant information.
Data extraction was undertaken by two reviewers; dual data
extraction was not conducted but both reviewers were trained
in data extraction and therefore inter-rater reliability was
expected to be good [19].
Two reviewers also independently assessed the methodo-
logical quality of the included full-text studies, utilising an 18-
question checklist that was adapted from several sources [20–
22]. Included conference abstracts were not quality assessed
because they were considered unlikely to provide sufficient
methodological information to enable an accurate assessment
of study quality.
All disagreements between reviewers during screening
and quality assessment were resolved by discussion and
consensus. No arbitration by a third party was necessary.
Data analysis methods for circumstances where suffi-
cient evidence for quantitative synthesis were available was
initially planned but where this was not considered feasible
(e.g. due to insufficient available evidence) a narrative
synthesis of results was conducted.
Results
Search Results and Studies Included
A flow diagram of the search results and screening process
is outlined in Fig. 1. Six full-text papers [13, 17, 23–26]
and ten abstracts [27–36] reporting the results of four trials
and one additional retrospective cohort, met our inclusion
criteria. The main reason for the exclusion of full-text
papers not meeting the review inclusion criteria are
provided in Table 1.
Corresponding authors were contacted for nine studies
(reported in a total of 14 papers) to clarify and determine
study inclusion or exclusion. Four authors (28.6%)
responded. In three instances the studies were excluded
(personal communication, P Rutkowski and P Wolter, Jan
2010) and in one instance [26], the study was included. It
was necessary to exclude the remaining ten papers, as
clarification was not provided [37–41].
No RCTs or non-randomised comparative studies were
found that directly compared the effectiveness of imatinib
at escalated doses (600 or 800 mg/day) with either sunitinib
or best supportive care. One on-going trial comparing an
escalated imatinib dose with sunitinib was identified, but
this trial had been stopped due to poor recruitment [42].
Relevant data were reported in five full-text reports of
three RCTs. These were:
– EORTC-ISG-AGITG (62005) trial, as reported by
Zalcberg and colleagues [17] and Debiec-Rychter and
colleagues [24], with one additional abstract reporting
interim data [36].
– S0033 trial as reported by Blanke and colleagues
[13], with two additional abstracts reporting interim data
[27, 29].
– B2222 trial as reported by Blanke and colleagues [23],
and Demetri and colleagues [43].
Each trial compared randomisation to 400 mg/day
imatinib with randomisation to a high (e.g. 600 mg/day or
800 mg/day) dose. Each of these papers reported separate
data on the outcomes of patients initially randomised to
400 mg/day who went on to receive an escalated dose only
upon progression at this dose. As these participants were
randomised to the 400 mg/day arm but were not further
randomised to an escalated dose on progression, the data
3366 titles and abstracts identified from primary searches
925 selected for full text assessment 
16 articles included 
2441 excluded
909 articles excluded 
(see Table 1 for reasons 
for exclusion) 
Fig. 1 Flow diagram outlining
the screening process for the
review of clinical effectiveness
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are essentially observational even though they are derived
from RCTs.
The escalated dose for the EORTC-ISG-AGITG and
S0033 trials was 800 mg/day [13, 17], while for the B2222
trial it was 600 mg/day [23].
In addition, one full-text paper of a non-randomised
retrospective study by Park and colleagues, was also
included, as it contained data on two groups of patients
receiving each of the escalated doses upon progression at
400 mg/day [26].
For sunitinib, seven abstracts met the inclusion criteria
[28, 30–35]. All related to an on-going, open-label sunitinib
trial reporting information on participants recruited to the
trial following failure at a variety of different doses of
imatinib, and reported separate information for a prior
imatinib dose of ≤400 mg/day. The abstract by Seddon and
colleagues [35] was considered the most recent and
therefore designated the primary report for this study.
Corresponding authors of each included trial were
contacted to determine whether any additional data could
be provided for the relevant study population within the
timeframe of this review. Data for the S0033 trial were
provided by the authors (personal communication, C
Rankin, February 2010).
Data were extracted for all outcomes of interest. No
study reported data on disease-free survival or health-
related quality of life. Baseline characteristics for the
relevant study population (i.e. those who received escalated
imatinib doses) were reported in two studies [17, 26].
Results of the quality assessment are provided in Fig. 2.
Study quality was similar for all imatinib studies, though
Table 1 Reasons for exclusion of studies
Reason for exclusion Number of
studies
excluded
Patient had resectable GIST 24
Outcomes not reported separately for GIST
patients
10
<10 patients in relevant study population 46
Imatinib dose is 400 mg/day 13
No/insufficient data reported for escalated
dose patients
66
No imatinib dose reported 84
No relevant interventions 15
Treatment not evaluated 11
No outcomes of relevance 10
Other reason 61
340





Case study/case series <10 patients 64
Non-English language exclusions 123
Not obtained 47
Total 909
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
The analyses adjusted for confounding factors?
Important prognostic factors identified?
Lost to follow-up likely to introduce bias? 
Non-respondents, dropouts explained?
Follow up long enough to measure outcomes?
Assessment of main outcomes blinded?
Valid and reliable outcome measure/s used?
Important outcomes considered?
Facilities used for treatment explained?
Procedure of intervention performance explained?
Clear description of intervention?
Prospective data collection?
Consecutive sample selection?
Similarity in disease progression at study entry?
Inclusion/exclusion clearly described?




Fig. 2 Quality assessment of included full-text papers
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assessment was complicated as the population of interest
was a subgroup within each trial and therefore data were
observational. None of the studies had a consecutive
sample selection, had considered all the important out-
comes of relevance or blinded outcome assessment, or had
clearly adjusted for confounding factors. However, all had
used valid and reliable outcome measures, described
inclusion and exclusion criteria, and the interventions
clearly and had collected data prospectively. Assessment
with the remaining quality criteria was unclear for all
studies or varied between studies.
Clinical Outcome Results for Dose Escalation of Imatinib
or Sunitinib
Outcome results reported for each of the included imatinib
studies are provided in Table 2. Additional data on specific
adverse events were provided for the relevant study
population only for the EORTC-ISG-AGITG trial [17].
Following dose escalation to 800 mg/day, a significantly
lower rate of neutropenia was observed (p=0.002). How-
ever, among the same population, significantly higher rates
of anaemia and fatigue (p=0.015 and p<0.001, respectively)
were observed [17].
With regard to mutational analysis, Debiec-Rychter and
colleagues in secondary analysis for the EORTC-ISG-
AGITG trial demonstrated that response following dose
escalation was significantly more likely to occur in patients
with wild-type KIT GISTs compared with those with KIT
exon 11 mutations (p=0.0012), and was also significantly
more likely to occur in patients with KIT exon 9 mutations
compared with KIT exon 11 mutations (p=0.0017), though
no figures were reported for the number of patients
involved [24].
For sunitinib, overall survival was reported by Seddon
and colleagues as being 90 weeks (95% CI 73 to 106 weeks)
Table 2 Results from included imatinib studies
Drug (dose) Imatinib (600 mg/day) Imatinib (800 mg/day)




12 43 12 118 133




8 months (1.4 to
22.3 months)
54 months (NR) 25 months
(NR to
35 months)
N (%) with response NR NR NR 3/117 (2.6%) 3/133 (2.3%)
N (%) with stable disease NR NR NR 33/117 (28.2%) 36/133 (27.0%)
Total N(%) with response
or stable disease
5/12 (41.7%) 11/43 (25.6%)b 4/12 (33.3%) 36/117 (30.8%) 39/133 (29.3%)
Median overall
survival (95% CI)a
NR NR NR 19 months (13 to
23 months)
NR
N (%) still alive NR NR NR 42/118 (35.6%) NR
Progression-free
survival (95% CI)a











NR NR NR 5.5 months
(range: 1.3 to
20.5 months)d
Disease free survival NR NR NR NR NR
Health related quality
of life
NR NR NR NR NR
N (%) discontinuations
due to adverse events
NR NR NR NR 11/97 (11.6%)c
N(%) with ≥1 dose delay NR NR NR 18/77 (23.3%) NR
N(%) with ≥1 dose
reduction
NR NR NR 12/77 (15.6%) NR (31%)
NR not reported
a Unless explicitly stated to be a reported range
b One patient only achieved response/stable disease following further dose escalation to 800 mg/day
c Figure estimated from data reported in the paper
d Unit of measurements has been converted to months by dividing by 28 (for days), dividing by 4 (weeks), or multiplying by 12 (years)
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for those receiving sunitinib upon progression with an
imatinib dose of ≤400 mg/day. However, the median follow
up time (51 weeks, 95% CI 0.1 to 159 weeks) was only
available for the entire study population (i.e. regardless of
prior imatinib dose). Of those receiving sunitinib after
progression on the ≤400 mg/day imatinib dose 193/351
(55%) were still alive at the time of analysis [35].
Overall survival with the escalated 800 mg/day dose of
imatinib was compared with sunitinib at a dose of 50 mg
for patients who had progressed on imatinib at a dose of
≤400 mg/day using data for the S0033 trial provided by
authors, and quarterly overall survival estimates reported in
a Kaplan–Meier chart by Seddon and colleagues, employing
the method proposed by Parmar and colleagues [44] (Fig. 3).
A meta-analysis of available Kaplan–Meier data for
progression-free survival for the EORTC-ISG-AGITG and
S0033 trials of the escalated 800 mg/day imatinib dose was
attempted using the method described by Arends and
colleagues [45], but was not possible due to lack of data. A
visual description of the progression-free survival results
from these studies is provided in Fig. 4.
Discussion
This systematic reviewwas performed to address the question:
“What is the most effective management strategy for patients
with advanced GISTs who have progressed following initial
therapy with imatinib 400 mg/day?” Dose escalation of
imatinib, sunitinib, and best supportive care were the options
considered. The review of the evidence base was detailed and
thorough, and a large number of full-text papers were assessed
against the inclusion criteria. Non-English language studies
were reviewed, and attempts were made to contact study
authors for clarification and additional data.
The data show that following dose escalation of imatinib,
approximately one-third of patients achieved a partial
response or stable disease. Over a median follow-up of over
2 years, more than half (i.e. 44/75 or 58.7%) of those who
showed response or stable disease on the 800 mg/day
escalated dose remained progression free. Dose escalation
appeared to be well tolerated, for most patients, althoughmore
fatigue and myelosuppression were observed.
Overall survival was less than 2 years for both those
receiving the 800 mg/day imatinib dose and those receiving
sunitinib. However, given the nature of the evidence base it
is difficult to draw any conclusions regarding possible
differences in survival between treatments.
One possible explanation for the guidance advocating
dose escalation so widely is the extent of the anecdotal
evidence for its effectiveness in clinical practice and the
evidence (observed disease control rates of 30% with 59%
of these patients remaining progression free for over 2 years
after dose escalation) supports this. Another explanation is
that the effectiveness of high dose imatinib as an initial
treatment is assumed to also apply to escalated dosing
(which may not be clinically or biologically valid). Within
our study these data on initial high imatinib dosing were
Fig. 3 Comparison of overall survival estimates for imatinib at 800 mg/day [13] and sunitinib at 50 mg [34]
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excluded because this represents a clinically and biologi-
cally distinct model from dose escalation upon progression,
especially in terms of distinct mechanisms for primary or
acquired resistance to high dose imatinib. It would not be
valid to assume that these mechanisms would be the same
for those receiving high-dose imatinib initially, as for those
patients who receive initial 400 mg dosing, become
resistant, and are subjected to dose escalation at that point.
Clinical practice may be changing to enable mutational
status to be used to tailor a patient’s initial imatinib dose in
future. With regard to imatinib dose escalation, the
mutational status of the 16 (600 mg/day) and 75 patients
(800 mg/day) showing response or stable disease with
escalated imatinib doses in this review was not known.
Evidence of the effectiveness of imatinib dose-escalation on
these patient subgroups therefore remains lacking, although
the EORTC-ISG-AGITG trial results reported (using p
values only) that wild-type KIT and exon nine mutations
were significantly more likely to respond to escalated doses
compared with those with exon 11 mutations [24]. Even if
clinical practice changes to recommend patients with exon
nine or wild-type KIT receive high doses of imatinib from
commencement of treatment rather than on progression at
the standard dose, evidence on the effectiveness of dose
escalated imatinib will still be necessary for patients who
do not have these particular mutations.
Limitations
The non-randomised, observational nature of the available
data is prone to a range of biases (e.g. confounding). In
addition, none of the studies distinguished between whether
participants had shown progression or whether they had
shown intolerance to imatinib at 400 mg/day. For the included
sunitinib trial it was necessary to assume that the majority of
the participants receiving “≤400 mg/day” had received the
actual dose of 400 mg/day, rather than lower doses. No ‘off-
licence’ treatments for GIST were considered (e.g. doses
exceeding 800 mg/day or continuous daily dosing of
sunitinib). Surgical interventions were also not considered,
even though they may offer an important treatment option
(e.g. in emergencies as part of best supportive care, or if drug
treatment shrinks tumours sufficiently to enable resection).
Conclusions and Recommendations
This review demonstrates that although dose escalation is
widely recommended within clinical guidance documents
[8–10], the actual evidence for its effectiveness among the
unresectable and/or metastatic GIST population after
progression at the standard 400 mg/day imatinib dose is
based solely on the results of several sets of observational
data reported within wider RCT evidence on the effective-
ness of standard versus high doses of imatinib.
Ideally, the existing evidence base could be improved
with new RCT evidence, but this is unlikely to be feasible
or appropriate given both the low incidence and the nature
of the disease. However, well-designed, non-randomised
studies could potentially help guide policy development on
treatment for this population group.
Imatinib and sunitinib trialists with access to existing
evidence on dose escalation outcomes (particularly for
Fig. 4 Comparison between two studies of progression free survival estimates with imatinib at 800 mg/day [13, 17]
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patients of differing mutational status) should consider
publishing these data separately if this has not already been
done, or attempt to pool existing patient-level data. Sixty-
six studies were excluded from this review because they
had not reported any separate information for dose
escalated patients, and a further 84 studies were excluded
because they did not report any information on imatinib
dose (including sunitinib studies not reporting information
on the prior imatinib dose received by the study popula-
tion). It is therefore possible that pooling any existing
unpublished patient level data could help clarify the
comparative effectiveness of dose escalation upon progres-
sion on the 400 mg/day imatinib dose.
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